Caffeine as a promoter of analgesic-associated nephropathy - Where is the evidence?

Fundamental and Clinical Pharmacology

Volumn 17, Issue 3, 2003, Pages 377-392

  Fox, Johannes M ^a   Siebers, Ute ^b  

^a St Marien Hospital   (Germany)

^b NONE

Author keywords

Analgesic combinatios; Analgesic overdosing; Analgesic associated nephropathy; Caffeine; Phenacetin; Review of source data

Indexed keywords

ANALGESIC AGENT; CAFFEINE;

ANALGESIC ACTIVITY; ANALGESIC AGENT ABUSE; ANALGESIC NEPHROPATHY; ARTICLE; DISEASE ASSOCIATION; DRUG OVERDOSE; EVIDENCE BASED MEDICINE; HUMAN; NEPHROLOGY; OBSERVATION; PRIORITY JOURNAL; PUBLICATION;

ANALGESICS; CAFFEINE; CLINICAL TRIALS; CODEINE; DRUG COMBINATIONS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PHENACETIN;

EID: 0038772216     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00174.x     Document Type: Article

References (129)

1. McCredie M., Stewart J.H., Mahony J.F. Is phenacetin responsible for analgesic nephropathy in New South Wales? Clin. Nephrol. (1982) 17 134-140.
2. Elseviers M.M., De Broe M.E. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int. (1995) 48 1912-1919.
3. Dubach U.C., Rosner B., Stürmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968-1987). N. Engl. J. Med. (1991) 324 155-160.
4. Pommer W., Bronder E., Greiser E., Helmert U., Jesdinsky H.J., Klimpel A., Borner K., Molzahn M. Regular analgesic intake and the risk of end-stage renal failure. Am. J. Nephrol. (1989) 9 403-412.
5. Morlans M., Laporte J-R., Vidal X., Cabeza D., Stolley P.D. End-stage renal disease and non-narcotic analgesics: a case-control study. Br. J. Clin. Pharmacol. (1990) 30 717-723.
6. Sandler D.P., Weinberg C.R. Analgesic use and chronic renal disease. N. Engl. J. Med. (1989) 321 1126-1127.
7. Buckalew V.M., Schey H.M. Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Medicine (Baltimore) (1986) 11 291-303.
8. Murray R.M. Genesis of analgesic nephropathy in the United Kingdom. Kidney Int. (1978) 13 50-57.
9. Gault M.H., Rudwal T.C., Engles W.D., Dossetor J.B. Syndrome associated with the abuse of analgesics. Ann. Intern. Med. (1968) 68 906-925.
10. Grimlund K. Phenacetin and renal damage at a Swedish factory. Acta. Med. Scand. (1963) 174 (Suppl. 405) 1-26.
11. Laska E.M., Sunshine A., Zighelboim I., Roure C., Marrero I., Wanderling J., Olson N. Effect of caffeine on acetaminophen analgesia. Clin. Pharmacol. Ther. (1983) 33 498-509.
12. Winter L., Appleby F., Ciccone P.E., Pigeon J.G. A doubleblind, comparative evaluation of acetaminophen, caffeine, and the combination of acetaminophen and caffeine in outpatients with post-operative oral surgery pain. Curr. Ther. Res. (1983) 33 115-121.
13. Goldstein J., Hoffman H.D., Armellino J.J., Battikha J.P., Hamelsky S.W., Couch J. et al. Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirine, and caffeine. Cephalalgia (1999) 19 1-8.
14. Lipton R.B., Stewart W.F., Ryan R.E. Jr, Saper J., Silberstein S., Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain. Arch. Neurol. (1998) 55 210-217.
15. Zhang W.Y., Li Wan Po A. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain: a meta-analysis. J. Clin. Pharm. Ther. (1996) 21 261-282.
16. Migliardi J.R., Armellino J.J., Friedmann M., Gillings D.B., Beaver W.T. Caffeine as an analgesic adjuvant in tension headache. Clin. Pharmacol. Ther. (1994) 56 576-586.
17. Murray R.M. Patterns of analgesic use and abuse in medical patients. Practitioner (1973) 211 639-644.
18. Stewart J.H. Analgesic abuse and renal failure in Australia. Kidney Int. (1978) 13 72-78.
19. Prescott L.F. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs (1982) 23 75-149.
20. Scheler F., Schoel G. Analgetikabusus unter spezieller Berücksichtigung der Analgetika-Nephropathie. Internist (1986) 27 770-777.
21. Robinson R.R., Cotran R.S., Derryberry J.S. et al. Consensus Conference of the Office of Medical Applications, NIH: Analgesic-Associated Kidney Disease. JAMA (1984) 251 3123-3125.
22. Henrich W.L., Agodoa L.E., Barrett B. et al. Analgesics and the kidney; summary and recommendations to the scientific advisory board of the national kidney organisation from an ad hoc committee of the national kidney foundation. Am. J. Kidney Dis. (1996) 27 162-165.
23. Hörl W.H. Kommentar zu Arbeit: Zweckmäßigkeit fixer Analgetikakombinationen am Beispiel von Thomapyrin. Wien Klin Wochenschr (1997) 109/7 255-256.
24. Delzell E., Shapiro S. Commentary on the National Kidney Foundation position paper on analgesics and the kidney. Am. J. Kidney Dis. (1996) 28 783-785.
25. Feinstein A.R., Heinemann L.A.J., Curhan G.C. et al. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Relationship between nonphenacetin combined analgesics and nephropathy: a review. Kidney Int. (2000) 58 2259-2264.
26. Feinstein A.R., Heinemann L.A.J., Dalessio D., Fox J.M., Goldstein J., Haag G., Ladewig D., O'Brien C.P. Ad Hoc Review Committee. Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin. Pharmacol. Ther. (2000) 68 457-467.
27. Kincaid-Smith P. Analgesic nephropathy. Kidney Int. (1978) 13 1-4.
28. Kincaid-Smith P. Effects of non-narcotic analgesics on the kidney. Drugs (1986) 32 109-128.
29. Delzell E., Shapiro S. A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine (Baltimore) (1998) 77 102-121.
30. McLaughlin J.K., Lipworth L., Chow W-H., Blot W.J. Analgesic use and chronic renal failure: A critical review of the epidemiologic literature. Kidney Int. (1998) 54 679-686.
31. Mc Credie M., Stewart J.H., Mathew T.H., Disney A.P.S., Ford J.M. The effect of withdrawal of phenacetin-containing analgesics on the incidence of kidney and urothelial cancer and renal failure. Clin. Nephrol. (1989) 31 35-39.
32. Dubach U.C., Levy P.S., Minder F. Epidemiological study of analgesic intake and its relationship to urinary tract disorders in Switzerland. Helv. Med. Acta (1968) 34 297-312.
33. Dubach U.C., Levy P.S., Müller A. Relationships between regular analgesic intake and urorenal disorders in a working female population of Switzerland. I. Initial results (1968). Am. J. Epidemiol. (1971) 93 425-434.
34. Dubach U.C., Levy P.S., Ehrensperger T., Baumeler H.R., Müller A., Peier A., Rosner B. Zusammenhang zwischen regelmäßiger Einnahme phenazetinhaltiger Analgetika und Nierenschädigung. Prospektive epidemiologische Schweizer Studie 1968-1972. Schweiz. Med. Wochenschr. (1974) 104 992-996.
35. Dubach U.C., Levy P.S., Rosner B., Baumeler H.R., Müller A., Peier A., Ehrensperger T. Chronic renal disease. Lancet (1975) 990.
36. Dubach U.C., Rosner B., Müller A., Levy P.S., Baumeler H.R., Peier A. Relation between regular intake of phenacetin-containing analgesics and laboratory evidence for urorenal disorders in a working female population of switzerland. Lancet (1975) 539-543.
37. Dubach U.C., Rosner B., Levy P.S., Baumeler H.R., Müller A., Peyer A., Ehrensperger T., Ettlin C. Epidemiological study in Switzerland. Kidney Int. (1978) 13 41-49.
38. Dubach U.C., Rosner B., Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N. Engl. J. Med. (1983) 308 357-362.
39. Dubach U.C., Rosner B., Stürmer T. Epidemiological study of analgesic abuse: mortality study in 7275 working women (1968-1987). Kidney Int. (1991) 40 728-733.
40. Murray T.G., Stolley P.D., Anthony J.C., Schinnar R., Hepler-Smith E., Jeffreys J.L. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch. Intern. Med. (1983) 143 1687-1693.
41. Perneger T.V., Whelton P.K., Klag M.J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N. Engl. J. Med. (1994) 331 1675-1679.
42. Pernegger T.V. Kidney failure and analgesic drugs. N. Engl. J. Med. (1995) 332 1515-1516.
43. Gates T.N., Temple A.R. Analgesic use and chronic renal disease. N. Engl. J. Med. (1989) 321 1126.
44. McCredie M. Analgesic use and chronic renal disease. N. Engl. J. Med. (1989) 321 1125-1126.
45. Mandel J.S. Analgesic use and chronic renal disease. N. Engl. J. Med. (1989) 321 1126.
46. Sandler D.P., Weinberg C.R. Analgesic use and chronic renal disease - a reply. N. Engl. J. Med. (1989) 321 1126-1127.
47. Sandler D.P., Burr F.R., Weinberg C.R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann. Intern. Med. (1991) 115 165-172.
48. Steenland N.K., Thun M.J., Ferguson C.W., Port F.K. Occupational and other exposures associated with male end-stage renal disease. A case-control study. Am. J. Public Health (1990) 80 153-159.
49. Burry A.F. The evolution of analgesic nephropathy. Nephron (1967) 5 185-201.
50. Burry A.F., Axelsen R.A., Trolove P. Analgesic nephropathy: its present contribution to the renal mortality and morbidity profile. Med. J. Aust. (1974) 1 31-36.
51. Kincaid-Smith P. The pathogenesis of the lesions associated with analgesic abuse. Lancet (1967) 1 859-862.
52. Kincaid-Smith P., Saker B.M., McKenzie I.F.C., Muriden K.D. Lesions in the blood supply of the papilla in experimental analgesic nephropathy. Med. J. Aust. (1968) 203-206.
53. Kincaid-Smith P. Analgesic nephropathy: a common form of renal disease in Australia. Med. J. Aust. (1969) 2 1131-1135.
54. Kincaid-Smith P., Nanra R.S., Fairley K.F. Analgesic nephropathy: a recoverable form of chronic renal failure, in Kincaid-Smith P., Fairley K. (Eds). Renal Infection and Renal Scarring, Mercedes Publishing Services, Melbourne. 1971. pp. 385-400.
55. Kincaid-Smith P., Whitworth J., Fairley K.F., Nanra R.S. Clinical course of analgesic nephropathy with renal failure, in: Haschek H. (Ed.), Internationales Symposium über Probleme des Phenacetin Abusus, Wien, 29-30 November 1973. Facta Publication, Verlag H, Egermann, 1973, pp. 157-184.
56. Kincaid-Smith P. Analgesic abuse and the kidney. Kidney Int. (1980) 17 250-260.
57. Kincaid-Smith P., Nanra R.S. Lithium-induced and analgesic-induced renal diseases, in: Schrier R.W., Gottschalk C.R. (Eds), Diseases of the Kidney, Little Brown, Boston, 1988, pp. 1197-1227.
58. Nanra R.S., Kincaid-Smith P. Chronic effect of analgesics on the kidney. Prog. Biochem. Pharmacol. (1972) 7 285-323.
59. Nanra R.S., Stuart-Taylor J., Deheon A.H., White K.H. Analgesic nephropathy: etiology, clinical syndrome and clinicopathologic correlations in Australia. Kidney Int. (1978) 13 79-92.
60. Nanra R.S. Clinical and pathological aspects of analgesic nephropathy. Br. J. Clin. Pharmacol. (1980) 10 359S-368S
61. Nanra R.S. Analgesic nephropathy in the 1990s - an Australian perspective. Kidney Int. (1993) 44 86-92.
62. Stewart J.H., McCredie M., Disney A.P.S., Mathew T.H. Trends in incidence of end-stage renal failure in Australia. 1972-1991. Nephrol. Dial. Transplant. (1994) 9 1377-1382.
63. Brunner F.P., Selwood N.H. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Nephrol. Dial. Transpant. (1994) 9 1371-1376.
64. Michielsen P., De Schepper P. Analgesic nephropathy. N. Engl. J. Med. (1998) 339 48-49.
65. Vanherweghem J-L., Even-Adin D. Epidemiology of analgesic nephropathy in Belgium. Clin. Nephrol. (1982) 17 129-133.
66. Bennett W.M., De Broe M.E. Analgesic nephropathy - a preventable renal disease. N. Engl. J. Med. (1989) 320 1269-1271.
67. De Broe M.E., Elseviers M.M. Analgesic nephropathy - still a problem? Nephron (1993) 64 505-513.
68. De Broe M.E., Elseviers M.M., Bengtsson U., Mihatsch M.J., Molzahn M., Pommer W., Ritz E., Schwarz A. Analgesic nephropathy. Nephrol. Dial. Transplant. (1996) 11 2407-2408.
69. De Broe M.E., Elseviers M.M. Analgesic nephropathy. N. Engl. J. Med. (1998) 338 446-452.
70. Elseviers M.M., De Broe M.E. Analgetika-Nephropathie in Belgien. Z. Urol. Nephrol. (1989) 82 127-134.
71. Elseviers M.M., Bosteels V., Cambier P. et al. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol. Dial. Transplant (1992) 7 479-486.
72. Elseviers M.M., De Broe M.E. Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures. Nephrol. Dial. Transplant. (1994) 9 41-46.
73. Elseviers M.M., De Schepper A., Corthouts R. et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int. (1995) 48 1316-1323.
74. Elseviers M.M., Waller I., Nenov D. et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Nephrol. Dial. Transplant. (1995) 10 808-814.
75. Elseviers M.M., De Broe M.E. Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Am. J. Kidney Dis. (1996) 28 48-55.
76. Noels L.M., Elseviers M.M., De Broe M.E. Health policies in nephrology. Impact of legislative measures on the scales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol. Dial. Transplant. (1995) 10 167-174.
77. Michielsen P., De Schepper P. Analgesic nephropathy in Belgium: confusion between prevalence and incidence. Am. J. Kidney Dis. (1996) 28 958-960.
78. Bengtsson U. Analgetika-Nephropathie-Langfristige Erfahrungen aus Schweden. Z. Urol. Nephrol. (1989) 82 121-125.
79. Nordenfelt O. Deaths from renal failure in abusers of phenacetin-containing drugs. Acta Med. Scand. (1972) 191 11-16.
80. Gsell O., Dubach U.C., Raillard-Peucker U. Phenacetinabusus und Nierenleiden. Dtsch. Med. Wochenschr. (1968) 93 101-108.
81. Kielholz P., Battegay R. Vergleichende Untersuchungen über die Genese und den Verlauf der Drogenabhängigkeit und des Alkoholismus. Schweiz. Med. Wochenschr. (1967) 97 944-949 and 893-898.
82. Battegay R. Aktuelle Aspekte der Analgeticasucht. Nervenarzt (1958) 29 467-468.
83. Battegay R. Individuelle und soziale Ursachen, Prognose und Prophylaxe der Sucht mit Analgetica. Schweiz. Med. Wochenschr. (1958) 89-92.
84. Ladewig D. Entstehung und Auswirkungen der Medikamentenabhängigkeit. Medizinisches Laboratorium (1969) 22 171-177.
85. Hobi V., Ladewig D., Dubach U.C., Miest P.C., Ehrensberger T. Analgesic abuse and personality characteristics. Int. J. Clin. Pharmacol. (1976) 13 36-41
86. Ladewig D., Miest P.C., Dubach U.C., Ettlin C., Hobi V. Use and abuse of non-narcotic analgesics. Drug Alcohol Depend. (1978) 3 435-442
87. Ladewig D., Meng H. Medikamenten- und Drogenabhängigeit bei Patienten psychiatrischer Kliniken. Schweiz. Rundsch. Med. Prax. (1983) 72 982-986.
88. Ladewig D. Analgetikamißbrauch und-abhängigkeit. Münch Med. Wochenschr. (1984) 126 1201-1204.
89. Ladewig D., Schroeter U. Mißbrauch und Abhängigkeit von Medikamenten und Drogen. Schweiz. Apoth. Ztg. (1988) 126 552-557.
90. Ladewig D. The abuse of non-narcotic analgesics, in: Stewart J.H. (Ed), Analgesic and NSAID-Induced Kidney Disease. Oxford University Press, Oxford, (1993) pp. 48-57.
91. Ladewig D. Communication at the New York Meeting Jan 19, 2000 (results published in 26).
92. Pommer W., Glaeske G., Molzahn M. The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences. Clin. Nephrol. (1986) 26 273-278.
93. Pommer W., Molzahn M. Die Analgetikanephropathie. Internist (1996) 37 1129-1136.
94. Bronder E., Klimpel A., Pommes W., Molzhan M. Daten zum chronischen Schmerzmittel gebranel. Soz. Praeventivmed. (1990) 35 147-151.
95. Meiner E. Analgetika-Verbrauch in Deutschland und ausgewählten Ländern. Pharm. Ind. (1987) 49 1247-1251.
96. Schneider R., Aicher B. Der Analgetikaverbrauch von 1970 bis 1995 im internationalen Vergleich. Pharm. Ztg. (1999) 33 26-29.
97. Schwarz, Preuschof L., Zellner D. Incidence of analgesic nephropathy in Berlin since 1993. Nephrol. Dial. Transplant. (1999) 14 109-112.
98. Fox J.M. Doubts about a particularly high nephrotoxicity of combination analgesics. Nephrol. Dial. Transplant. (1999) 14 2966-2968.
99. Schwarz A. Nephrotoxicity of combination analgesics: reply. Nephrol. Dial. Transplant. (1999) 14 2968-2969.
100. Schwarz A., Faber U., Borner K., Keller F., Offermann G., Molzahn M. Reliability of drug history in analgesic users. Lancet (1984) 1163-1164.
101. Schwarz A. Analgesic-associated nephropathy. Klin. Wochenschr. (1987) 65 1-16.
102. Abbott F.V., Fraser M. Use and abuse of over-the-counter analgesic agents. J. Psychiatry Neurosci. (1998) 23 13-34.
103. Gault M.H., Rudwal T.C., Redmond N.I. Analgesic habits of 500 veterans: incidence and complications of abuse. Can. Med. Assoc. J. (1968) 98 619-626.
104. Gault M.H., Shahidi N.T., Gabe A. The effect of acetylsalicylic acid, caffeine, and codeine on the excretion of phenacetin metabolites. Can. J. Physiol. Pharmacol. (1972) 50 809-816.
105. Gault M.H., Wilson D.R. Analgesic nephropathy in Canada: clinical syndrome, management, and outcome. Kidney Int. (1978) 13 58-63.
106. Wilson D.R. II. Analgesic nephropathy in Canada: a retrospective study of 351 cases. Can. Med. Assoc. J. (1972) 107 752-755.
107. Prescott L.F., Steel R.F., Ferrier W.R. The effects of particle size on the absorption of phenacetin in man. A correlation between plasma concentration of phenacetin and effects on the central nervous system. Clin. Pharmacol. Ther. (1970) 11 496-504.
108. Angervall L., Bengtsson U., Zetterlund C.G., Zsigmond M. Renal pelvic carcinoma in a Swedish district with abuse of a phenacetin-containing drug. Br. J. Urol. (1969) 9 401-405.
109. Bengtsson U. Long-term pattern in chronic pyelonephritis. Contrib. Nephrol. (1979) 16 31-36.
110. Mabeck C.R., Wichmann B. Mortality from chronic interstitial nephritis and phenacetin consumption in Denmark. Acta Med. Scand. (1079) 205 599-601.
111. Sillanpää M, Kasanen A, Elonen A. Changes of panorama in renal disease mortality in Finland after phenacetin restriction. Acta. Med. Scand. (1982) 212 313-317.
112. Nelson E.B. Kidney failure and analgesic drugs. N. Engl. J. Med. (1995) 332 1514-1515.
113. Faich G., Nelson E.B., Horowitz R.S., Wilson V.L., Dart R.C., Perneger T.V., Whelton P.K., Klag M.J. Kidney failure and analgesic drugs. N. Engl. J. Med. (1995) 332 1514-1515.
114. Horowitz R.S. Kidney failure and analgesic drugs. N. Engl. J. Med. (1995) 332 1515-1516.
115. Wing A.J., Brunner F.P., Geerlings W., Broyer M., Brynger H., Fassbinder W., Rissoni G., Selwood N.H., Tufveson G. Contribution of toxic nephropathies to end-stage renal failure in Europe: a report from the EDTA-ERA registry. Toxicol. Lett. (1989) 46 281-292.
116. Carrociampi G. Phenacetin abuse: a review. Toxicology (1978) 10 311-339.
117. Saß H., Wittchen H.U., Zandig M. Diagnostisches und Statistisches Manual Psychischer Störungen (DSM-IV). Hogrefe Verlag für Psychologie - Göttingen Bern Toronto Seattle 1996.
118. Griffiths R.R., Mumford G.K. Caffeine - a drug of abuse?. In: Bloom F.E., Kupfer D.J. (Eds), Psychopharmacology - the Fourth Generation of Progress. Raven Press, New York. 1995, pp. 1699-1713.
119. Hughes J.R., Oliveto A.H., Helzer J.E., Higgins S.T., Bickel W.K. Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? Am. J. Psychiatry (1992) 149 33-40.
120. Dews P.B., Curtis G.L., Hanford K.J., O'Brien C.P. The frequency of caffeine withdrawal in a poulation-based survey and in a controlled, blinded experiment. Clin. Pharmacol. (1999) 39 1-12.
121. Nehlig A. Are we dependent upon coffee and caffeine? - a review on human and animal data. Neurosci. Biobehav. Rev. (1999) 23 563-576.
122. Headache Classification Comittee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia (1988) 8 9-96.
123. Scholz E., Diener H.C., Geiselhart S. Drug-induced headache - does a critical dosage exist?. in: Diener H.C., Wilkinson M. (Eds), Drug-Induced Headache, Springer-Verlag, Berlin, Heidelberg. 1988. pp. 29-43.
124. Baumgartner C., Wesseley P., Bingöl C., Maly J., Holzner F. Longterm prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache (1989) 29 510-514.
125. Rapoport A., Stand P., Gütterman D.L., Cady R., Markley H., Weeks R. et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache (1996) 36 14-19.
126. Tribl G.C., Schnider P., Wöber C. et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache. Cephalgia (2001) 21 691-696.
127. Fox J.M. Coffein plus Analgetika - eine sinnvolle Kombination. Der Schmerz (1988) 2 183-197.
128. Baron D.N. Accuracy of references in theses. Lancet (2001) 357 150.
129. Siefers R., Holt S. Accuracy of references in five leading medical journals. Lancet (2000) 356 1445.